AirSculpt Guides Above-Consensus Revenue; Bullish Stance On Oculis
- October 05th, 2023
- 651 views
AirSculpt Technologies, Inc. (Nasdaq: AIRS), a medical technology company specializing in body contouring procedures, has provided a positive outlook for its third-quarter 2023 revenue, with expectations set at approximately $46.5 million, surpassing the consensus estimate of $43.86 million.
Furthermore, the company has revised its full-year 2023 revenue guidance, anticipating approximately $196 million, up from the previous guidance range of $187 million to $192 million. The consensus revenue estimate stands at $192.23 million for the period.
In pre-market trading, $AIRS remains unchanged at $7.02.
In other news, Stifel has initiated coverage on Oculis Holding AG (Nasdaq: OCS), a notable player in the healthcare sector, granting it a Buy rating along with a price target of $35.
With $OCS closing at $11.07 on Wednesday, this price target implies a potential upside of $23.93 or approximately 216.09%, according to the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
September 04th, 2026Signing Day Is Not the End of Recruiting
September 04th, 2026Treasury, IRS Move to End Tax-Exempt Status for Discriminatory Practices in Private Schools
September 03rd, 2026FDA Approves First Drug to Treat Alexander Disease
September 03rd, 2026How Coaching Staffs Evaluate Athletes Across a Season
September 03rd, 2026
Member Login